
    the study stopped based on pfizer portfolio prioritization and not due to safety and/or
    efficacy concern or change in benefit:risk assessment of pf-04457845.
  
['post-traumatic stress disorder']
['pf-04457845', 'placebo']

        Inclusion Criteria:

          -  Men and women 18-60 years of age with a primary psychiatric diagnosis of Post
             Traumatic Stress Disorder

        Exclusion Criteria:

          -  Other psychiatric illness requiring current treatment with medication.
      